Validea's guru fundamental report highlights Bristol-Myers Squibb (BMY) with an 88% rating using its P/B Growth Investor model, based on Partha Mohanram's academically-backed strategy for identifying sustainable growth in low book-to-market stocks. This score, indicating 'some interest' for a large-cap biotech, suggests BMY aligns with criteria for future growth, despite failing the R&D to Assets test.
Bristol-Myers Squibb (BMY) has been identified as a noteworthy large-cap growth stock, scoring 88% on Validea's P/B Growth Investor model, which is based on an academic strategy by Partha Mohanram designed to find sustainable growth in low book-to-market companies. This high score, just shy of the 'strong interest' threshold of 90%, indicates a favorable quantitative profile. The company passed eight fundamental tests, demonstrating strength in its book-to-market ratio, return on assets (ROA), cash flow generation relative to assets, and stability in both ROA and sales. However, the analysis reveals a specific point of weakness, as BMY failed the test for 'Research and Development to Assets'. This suggests that while current operational and financial metrics are strong, its R&D spending may be considered low relative to its asset base according to this specific model's criteria, a notable factor for a firm in the Biotechnology & Drugs industry.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
